Selegiline for Smoking Cessation - 1

Completed · Phase 2 · Has a placebo group

Conditions studied: Nicotine Dependence

In brief

The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.

Key facts

Study ID

NCT00439413

Run by

National Institute on Drug Abuse (NIDA)

People needed

246

Starts

2007-06-01

Expected to finish

2009-01-01

Last updated by the study team

2017-02-02

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must be at least 18 years of age
• Be in good general health
• Must meet Diagnostic and Statistical Manual-IV (DSM-IV) diagnostic criteria for nicotine dependence
• Be currently smoking > 15 cigarettes/day, and have smoked cigarettes for the past 5 years
• Subjects must be motivated to quite smoking
• If female and of child bearing potential, agrees to use birth control and subject
• Subject must be able to understand and provide written informed consent.

You may not qualify if…

• Please contact site for more information

Where it is running

• Department of Public & Community Health — College Park, Maryland, United States
• Robert Wood Johnson Med School-Tobacco Dep Program — New Brunswick, New Jersey, United States
• Tri-State Tobacco and Alcohol Research Center — Cincinnati, Ohio, United States
• Center For Tobacco Research and Intervention — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.